About
Vinay Bhaskar, Ph.D., joined MPM in 2016 after leading External R&D for the Oncology therapeutic area at Amgen. In this role, Vin was instrumental in forging collaborations with companies such as Kite Pharma, Merck and Xencor. During this time he also led internal immuno-oncology strategy discussions and served as executive sponsor and/or board observer for several Amgen Ventures investments, including Surface Oncology, Precision BioSciences and Tizona Therapeutics, a company founded by MPM. Vin joined Amgen through its acquisition of Onyx Pharmaceuticals, where he led preclinical search, evaluation and diligence for licensing and acquisition opportunities on the Asset Acquisition Team. Prior to joining Onyx, Vin held a variety of roles of increasing responsibility in Discovery Research at Portola Pharmaceuticals, XOMA, PDL Biopharma and Eos Biotechnology. In these roles, he initiated and led multiple preclinical project teams and functional groups focused on biologies that spanned on
Position in the VCSift Database
- • 14 investors at MPM Capital are tracked.
- • 4 investors hold the Principal & Partner role in VCSift. Vin Bhaskar is one of them.
- • 7,285 investors are based in San Francisco, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- San Francisco, US
Contact Information
Find more investors like Vin
Search Investors